Article in Haematologica, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 35% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
2 citing papers in PubMed, 1 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
8 authors at 3 institutions in 1 country.
Raghda T FoudaHematology/Oncology, Department of Medicine, University of California, Irvine, CA.
Hemanth M CherukuryHematology/Oncology, Department of Medicine, University of California, Irvine, CA.
Stacy B KivenHematology/Oncology, Department of Medicine, University of California, Irvine, CA.
Natalie R GarciaHematology/Oncology, Department of Medicine, University of California, Irvine, CA.
Donovan A ArguetaHematology/Oncology, Department of Medicine, University of California, Irvine, CA.
Graham J VelascoPathology Department, VA Long Beach Medical Center, Long Beach, CA.
Kalpna GuptaHematology/Oncology, Department of Medicine, University of California, Irvine, CA, USA; Division of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, MN. kalpnag@hs.uci.edu.
John D RobertsYale University. john.d.roberts@yale.edu.
University of California, Irvine · USLong Beach Medical Center · USYale University · US
Funding
Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
Virus Vector Shared ResourceP30CA016059 · NCI · VIRGINIA COMMONWEALTH UNIVERSITY · PI Renato Martins · 1985 to 2026
$51.0M
University of California Health Participation in the National COVID Cohort Collaborative (N3C)UL1TR001414 · NCATS · UNIVERSITY OF CALIFORNIA-IRVINE · PI COOPER, DAN M, VILAIN, ERIC J. · 2015 to 2023
$35.1M
X-LINKED HYPOPHOSPHATEMIAM01RR000065 · NCRR · VIRGINIA COMMONWEALTH UNIVERSITY · PI CLORE, JOHN N. · 1985 to 2010
$24.8M
VCU Minority-Based Community Clinical Oncology ProgramU10CA052784 · NCI · VIRGINIA COMMONWEALTH UNIVERSITY · PI HACKNEY, MARY H · 1990 to 2014
$7.1M
Targeting mechanisms contributing to vascular dysfunction and pain in sickle cell diseaseR01HL147562 · NHLBI · UNIVERSITY OF CALIFORNIA-IRVINE · PI GUPTA, KALPNA · 2019 to 2022
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Colchicine reduces inflammation in a humanized transgenic murine model of sickle cell disease. · full record | OpenQuestion